The NPF is the leading patient advocacy group for more than 8.3 million Americans and the more than 105,000 Oregon residents living with psoriasis and psoriatic arthritis. I write to you today to express our support for HB 2517.
It is critical that patients can receive an exception to the required step therapy practice when the plan directed medication is inappropriate. Delays in treatment can have devastating health implications that are avoidable when patients have access to a timely, clear, and accessible exception request process. A recent study showsthat step therapy protocolsare inconsistent across payers, creating additional confusion and frustration for patients and their providers acting on their behalf. HB 2517would set a standard for the exception request process including timelines, clinical review criteria,and making the exception process transparent and straightforward.